切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2026, Vol. 15 ›› Issue (04) : 181 -187. doi: 10.3877/cma.j.issn.2095-3216.2026.04.001

论著

基于GEO数据挖掘探讨大黄-丹参药对干预糖尿病肾脏疾病的作用机制
石雨申1, 王旭1, 张艳霞1, 张静洁1, 苏静克2, 胡海娇2, 陈怡洁2, 王聪慧1, 耿燕秋1,()   
  1. 1100853 解放军总医院肾脏病医学部、肾脏疾病全国重点实验室、肾病与泌尿系统疾病国家临床医学研究中心、重症肾脏疾病器械与中西医药物研发北京市重点实验室、数智中医泛血管疾病防治北京市重点实验室、国家中医药管理局高水平中医药重点学科(zyyzdxk-2023310)、国家中医药管理局中医药创新团队及人才支持计划项目(ZYYCXTD-D-202402)
    2100039 北京,解放军总医院第三医学中心肾脏病科
  • 收稿日期:2026-05-07 出版日期:2026-08-28
  • 通信作者: 耿燕秋
  • 基金资助:
    国家自然科学基金(81903936)

Exploring the mechanism of the rhubarb-Salvia miltiorrhiza herb pair in the intervention of diabetic kidney disease based on GEO data mining

Yushen Shi1, Xu Wang1, Yanxia Zhang1, Jingjie Zhang1, Jingke Su2, Haijiao Hu2, Yijie Chen2, Conghui Wang1, Yanqiu Geng1,()   

  1. 1Senior Department of Nephrology, Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney and Urological Diseases, Beijing Key Laboratory of Medical Devices and Integrated Traditional Chinese and Western Drug Development for Severe Kidney Diseases, Beijing Key Laboratory of Digital Intelligent TCM for Prevention and Treatment of Pan-vascular Diseases, Key Disciplines of National Administration of Traditional Chinese Medicine (zyyzdxk-2023310), Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (ZYYCXTD-D-202402), Beijing 100853
    2Department of Nephrology, Third Medical Center of Chinese PLA General Hospital, Beijing 100039; China
  • Received:2026-05-07 Published:2026-08-28
  • Corresponding author: Yanqiu Geng
引用本文:

石雨申, 王旭, 张艳霞, 张静洁, 苏静克, 胡海娇, 陈怡洁, 王聪慧, 耿燕秋. 基于GEO数据挖掘探讨大黄-丹参药对干预糖尿病肾脏疾病的作用机制[J/OL]. 中华肾病研究电子杂志, 2026, 15(04): 181-187.

Yushen Shi, Xu Wang, Yanxia Zhang, Jingjie Zhang, Jingke Su, Haijiao Hu, Yijie Chen, Conghui Wang, Yanqiu Geng. Exploring the mechanism of the rhubarb-Salvia miltiorrhiza herb pair in the intervention of diabetic kidney disease based on GEO data mining[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2026, 15(04): 181-187.

目的

结合基因表达数据库(Gene Expression Omnibus,GEO)数据挖掘、网络药理学及分子对接技术,探讨大黄丹参药对干预糖尿病肾脏疾病的潜在作用机制。

方法

通过中药系统药理学数据库,结合《中国药典》及文献获取大黄丹参的有效成分与潜在靶标。检索GEO数据库中糖尿病肾脏疾病相关肾小球数据集GSE30528、肾小管数据集GSE30529;在两类组织中分别进行差异分析,筛选探索性候选靶点。利用互作基因/蛋白质搜索工具(Search Tool for Retrieval of Interacting Genes/Proteins,STRING)数据库进行蛋白互作分析,借助Cytoscape软件构建靶点网络,使用R语言对关键靶标进行基因本体(Gene Ontology, GO)功能注释与京都基因与基因组百科全书(Kyoto Encyclopedia of Genes and Genomes,KEGG)通路富集分析,最后采用AutoDock Vina开展分子对接验证。

结果

筛选出大黄丹参有效成分90个、潜在靶标150个,DKD候选差异靶标3 592个,共获得交集靶标43个。拓扑分析明确核心靶点为表皮生长因子受体、半胱天冬酶3、激酶插入结构域受体、丝裂原活化蛋白激酶1及细胞间黏附分子1,核心成分为大黄素、芦荟大黄素、丹参素、丹参酮ⅡA。GO功能富集于上皮细胞增殖与凋亡、细胞外信号调节激酶1/2级联反应及含胶原细胞外基质;KEGG主要富集于磷脂酰肌醇3-激酶/蛋白激酶B、丝裂原活化蛋白激酶、整合素及缺氧诱导因子-1信号通路。分子对接显示,大黄素和丹参酮ⅡA与核心靶点表皮生长因子受体的结合能分别为9.32、9.59 kcal/mol,均具有较好的理论结合活性。

结论

大黄丹参药对可能通过多成分、多靶点、多通路网络参与糖尿病肾脏疾病相关病理过程;大黄素、丹参酮ⅡA及表皮生长因子受体相关信号网络可作为后续体内外验证的候选方向。

Objective

To explore the potential mechanism of the rhubarb-Salvia miltiorrhiza herb pair in the intervention of diabetic kidney disease (DKD) by integrating Gene Expression Omnibus (GEO) data mining, network pharmacology, and molecular docking techniques.

Methods

Active ingredients and potential targets of rhubarb-Salvia miltiorrhiza were obtained through the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database combining with the Chinese Pharmacopoeia and relevant literature. The glomerular dataset GSE30528 and the tubular dataset GSE30529 related to DKD were retrieved from the GEO database, and differential analysis was performed in the two types of tissues to screen exploratory candidate targets. Protein-protein interaction analysis was performed using the STRING database, and the target network was constructed with Cytoscape software, while GO functional annotation and KEGG pathway enrichment analysis of key targets were conducted via R language. Finally, molecular docking verification was carried out using AutoDock Vina.

Results

From rhubarb-Salvia miltiorrhiza, a total of 90 active ingredients, 150 potential targets, and 3, 592 candidate differential targets for DKD were screened out, yielding a total of 43 intersecting targets. Topological analysis identified the core targets as EGFR, CASP3, ICAM1, KDR, and MAPK1, and the core components as emodin, aloe-emodin, danshensu, and tanshinone ⅡA. Go enrichment involved epithelial cell proliferation and apoptosis, ERK1/2 cascade reaction, and collagen-containing extracellular matrix. KEGG enrichment was mainly observed in PI3K/Akt, MAPK, integrin, and HIF-1 signaling pathway. Molecular docking showed that the binding energies of emodin and tanshinone ⅡA to the core target EGFR were -9.32 and -9.59 kcal/mol, respectively, both exhibiting favorable theoretical binding activity.

Conclusion

The rhubarb-Salvia miltiorrhiza herb pair may participate in the pathological processes associated with DKD through a multi-component, multi-target, and multi-pathway network. The signal networks related to emodin, tanshinone ⅡA, and EGFR can serve as candidate directions for subsequent in-vivo and in-vitro verification.

图1 大黄-丹参有效成分潜在靶点与DKD疾病靶点韦恩图注:紫色圆代表大黄-丹参药对筛选出的150个潜在药物靶点;黄色圆代表基于GEO数据库获取的3 592个DKD候选差异靶标;中间重叠部分代表43个共有交集靶标
图2 关键靶标蛋白互作网络与"有效成分-靶标"网络图注:A为共有关键靶标的PPI网络图——图中球形节点代表靶标蛋白,节点内部展示已知或预测的蛋白质三维结构,节点间的不同颜色连线代表不同类型的蛋白质相互作用证据(如实验验证、文本挖掘、共表达等);B为大黄-丹参药对"有效成分-靶标"调控网络图——中央的黄色矩形节点代表大黄与丹参的有效活性成分,外围的绿色椭圆形节点代表干预DKD的潜在关键靶标基因,灰色连线表示活性成分与对应靶标之间存在潜在的干预调控关系
图3 关键靶点的基因本体功能富集分析注:A为参与的生物学过程;B为所在的细胞组分;C为涉及的分子功能;图中仅展示各分类中显著性排序前5的富集条目,横轴表示基因比例与显著性-Log10(P值),图中的条形柱长度代表该条目的富集显著性,折线散点的大小代表富集到该条目上的靶基因数量
图4 关键靶点的京都基因与基因组百科全书(KEGG)通路富集分析气泡图注:图示显著性排序前10的富集通路;横轴为双重映射坐标,综合表示基因比例与显著性-Log10(P值);图中的条形柱长度代表该通路的富集显著性,折线散点的大小代表富集到该通路上的靶基因数量;KEGG,Kyoto Encyclopedia of Genes and Genomes,京都基因与基因组百科全书;PI3K-Akt,phosphatidylinositol 3-kinase/protein kinase B,磷脂酰肌醇3-激酶/蛋白激酶B;MAPK,mitogen-activated protein kinase,丝裂原活化蛋白激酶;HIF-1,hypoxia-inducible factor-1,缺氧诱导因子-1;TNF,tumor necrosis factor,肿瘤坏死因子;AGEs-RAGE,advanced glycation end-products/ receptor for advanced glycation end-products,晚期糖基化终末产物/晚期糖基化终末产物受体
图5 核心活性成分与关键靶点蛋白分子对接结合能热图注:横轴为受体蛋白(关键靶点),纵轴为配体分子(核心成分);热图内数值代表结合能大小(单位:kcal/mol);色阶由浅至深(即结合能绝对值越大)代表配体与受体结合的亲和力越强,构象越稳定
图6 大黄素与丹参酮ⅡA同核心靶点表皮生长因子受体三维对接构象细节图注:A为大黄素与核心靶点EGFR的结合模式图,局部放大显示其与MET-769、THR-766、LYS-721及ASP-831等氨基酸残基的相互作用;B为丹参酮ⅡA与核心靶点EGFR的结合模式图,局部放大显示其与LYS-721及ASP-831等氨基酸残基的相互作用;黄色虚线及数值代表配体与受体间形成的氢键作用力及距离;MET,methionine,甲硫氨酸;THR,threonine,苏氨酸;LYS,lysine,赖氨酸;ASP,aspartic acid,天冬氨酸;EGFR,epidermal growth factor receptor,表皮生长因子受体
[1]
Martinez Leon V, Hilburg R, Susztak K. Mechanisms of diabetic kidney disease and established and emerging treatments [J]. Nat Rev Endocrinol, 2026, 22(1): 21-35.
[2]
张睿敏,董哲毅,王倩,等. 肾小管间质纤维化生物标志物研究进展[J/OL]. 中华肾病研究电子杂志2025, 14(2): 91-96.
[3]
Rayego-Mateos S, Rodrigues-Diez RR, Fernandez-Fernandez B, et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030 [J]. Kidney Int, 2023, 103(2): 282-296.
[4]
Tang G, Li S, Zhang C, et al. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management [J]. Acta Pharm Sin B, 2021, 11(9): 2749-2767.
[5]
刘珺玲,卢世秀. 中西医结合治疗糖尿病肾病的研究进展[J/OL]. 中华中医药学刊:1-9 [2026-08-09].

URL    
[6]
刘昊祤. 基于文献研究中医药治疗糖尿病肾脏疾病各分期用药规律[D]. 沈阳:辽宁中医药大学,2025.
[7]
Danel T, Łęski J, Podlewska S, et al. Docking-based generative approaches in the search for new drug candidates [J]. Drug Discov Today, 2023, 28(2): 103439.
[8]
张丰丰,杨倩雯,陈晔欣,等. 糖尿病肾病中医病因病机、辨证论治及用药规律分析[J]. 中国实验方剂学杂志2026, 32(6): 246-253.
[9]
Wang L, Wang X, Li G, et al. Emodin ameliorates renal injury and fibrosis via regulating the miR-490-3p/HMGA2 axis [J]. Front Pharmacol, 2023, 14: 1042093.
[10]
Lu L, Li Y. Aloe-emodin ameliorates diabetic nephropathy by targeting interferon regulatory factor 4 [J]. Evid Based Complement Alternat Med, 2022, 2022: 2421624.
[11]
Zeng J, Bao X. Tanshinone IIA attenuates high glucose-induced epithelial-to-mesenchymal transition in HK-2 cells through VDR/Wnt/β-catenin signaling pathway [J]. Folia Histochem Cytobiol, 2021, 59(4): 259-270.
[12]
Xu L, Shen P, Bi Y, et al. Danshen injection ameliorates STZ-induced diabetic nephropathy in association with suppression of oxidative stress, pro-inflammatory factors and fibrosis [J]. Int Immunopharmacol, 2016, 38: 385-394.
[13]
Liu XJ, Hu XK, Yang H, et al. A review of traditional chinese medicine on treatment of diabetic nephropathy and the involved mechanisms [J]. Am J Chin Med, 2022, 50(7): 1739-1779.
[14]
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities [J]. Clin J Am Soc Nephrol, 2017, 12(12): 2032-2045.
[15]
Taniguchi K, Xia L, Goldberg HJ, et al. Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice [J]. Diabetes, 2013, 62(11): 3874-3886.
[16]
Liu S, Han S, Wang C, et al. MAPK1 mediates MAM disruption and mitochondrial dysfunction in diabetic kidney disease via the PACS-2- dependent mechanism [J]. Int J Biol Sci, 2024, 20(2): 569-584.
[17]
Lavoz C, Rodrigues-Diez RR, Plaza A, et al. VEGFR2 blockade improves renal damage in an experimental model of type 2 diabetic nephropathy [J]. J Clin Med, 2020, 9(2): 302.
[18]
Okada S, Shikata K, Matsuda M, et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes [J]. Diabetes, 2003, 52(10): 2586-2593.
[19]
Wei J, Wu H, Zhang H, et al. Anthocyanins inhibit high glucose-induced renal tubular cell apoptosis caused by oxidative stress in db/db mice [J]. Int J Mol Med, 2018, 41(3): 1608-1618.
[20]
Liu H, Wang Q, Shi G, et al. Emodin ameliorates renal damage and podocyte injury in a rat model of diabetic nephropathy via regulating AMPK/mTOR-mediated autophagy signaling pathway [J]. Diabetes Metab Syndr Obes, 2021, 14: 1253-1266.
[21]
Peng H, Zhang X. Tanshinone IIA suppresses the proliferation and fibrosis of mesangial cell in diabetic nephropathy though WTAP-mediated m6A methylation [J]. Sci Rep, 2025, 15(1): 21261.
[22]
Li X, Mei J. Advances in targeting the AGEs-RAGE pathway for the treatment of diabetic kidney disease [J]. Drug Des Devel Ther, 2026, 20: 586198.
[23]
Awad AS, You H, Gao T, et al. Macrophage-derived tumor necrosis factor-α mediates diabetic renal injury [J]. Kidney Int, 2015, 88(4): 722-733.
[24]
Stanigut AM, Pana C, Enciu M, et al. Hypoxia-inducible factors and diabetic kidney disease - how deep can we go?[J]. Int J Mol Sci, 2022, 23(18): 10413.
[25]
Jing D, Bai H, Yin S. Renoprotective effects of emodin against diabetic nephropathy in rat models are mediated via PI3K/Akt/GSK-3β and Bax/caspase-3 signaling pathways [J]. Exp Ther Med, 2017, 14(5): 5163-5169.
[1] 林蕊, 陈文昭, 刘嘉颖, 龙翔宇. 桃红四物汤治疗膝骨关节炎的疗效及机制研究[J/OL]. 中华关节外科杂志(电子版), 2026, 20(02): 206-214.
[2] 张子远, 姜笃银. 基于网络药理学和分子对接探讨沙棘促进烧烫伤创面修复的作用机制[J/OL]. 中华损伤与修复杂志(电子版), 2025, 20(05): 404-411.
[3] 刘璐, 封宝红. 基于网络药理学及生物信息学探讨冬瓜皮对动静脉内瘘成熟的潜在作用与机制[J/OL]. 中华肾病研究电子杂志, 2026, 15(03): 158-165.
[4] 王旭, 肖昀明, 石雨申, 刘冉, 耿晓东, 王聪慧, 朱晗玉, 洪权, 张利, 陈帅印. 基于网络药理学与分子对接技术探讨济生肾气丸治疗慢性肾衰竭的机制[J/OL]. 中华肾病研究电子杂志, 2026, 15(01): 21-28.
[5] 王柯云, 孙雅佳, 李甜, 张钰哲, 郑颖, 张伟光, 王倩, 董哲毅. 糖尿病肾脏疾病早期发生风险预测模型的研究进展[J/OL]. 中华肾病研究电子杂志, 2025, 14(04): 218-225.
[6] 张可颖, 冀雨薇, 付章宁, 张益帆, 王晓晨, 杨滟, 陈香美, 蔡广研, 洪权. 人参皂苷Rb1 预处理间充质干细胞的转录组分析及急性肾损伤治疗关键基因挖掘[J/OL]. 中华肾病研究电子杂志, 2025, 14(01): 26-33.
[7] 周学锋, 董哲毅, 冯哲, 蔡广研, 陈香美. 糖尿病肾脏疾病中西医结合诊疗指南计划书[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 301-305.
[8] 马俊, 韩卓君, 王子睿, 娄彦妮, 苏菲. 基于网络药理学、分子对接及分子动力学探究逍遥丸干预乳腺癌前病变的作用机制[J/OL]. 中华临床医师杂志(电子版), 2026, 20(03): 210-221.
[9] 唐梦楚, 段俗言, 王宁宁, 毛慧娟, 刘云. 胰高血糖素样肽-1受体激动剂应用于糖尿病肾脏疾病的进展更新[J/OL]. 中华临床医师杂志(电子版), 2025, 19(04): 307-314.
[10] 俞俊霞, 台宗光, 程婷婷, 朱全刚. 红花平疣颗粒治疗扁平疣的网络药理学分析及羟基红花黄色素A的含量测定[J/OL]. 中华临床医师杂志(电子版), 2023, 17(12): 1270-1276.
[11] 张敏洁, 王雅晳, 段莎莎, 施依璐, 付文艳, 赵海玥, 张小杉. 基于GEO数据库和生物信息学分析筛选大鼠心肌缺血再灌注损伤相关潜在通路和靶点[J/OL]. 中华临床医师杂志(电子版), 2023, 17(04): 438-445.
[12] 郭文秀, 吴胜男, 王小芸, 张敏. 基于网络药理学的百部联合川贝母治疗肺结核的作用机制研究[J/OL]. 中华临床医师杂志(电子版), 2023, 17(03): 335-342.
[13] 黄楠, 肖天池, 曾成粤, 莫乔惠, 张丽嬴, 徐淼源, 邓小燕, 梁晓丽. 基于网络药理学和分子对接探究桑菊感冒颗粒抗甲型H1N1流感的活性成分及作用机制[J/OL]. 中华临床实验室管理电子杂志, 2023, 11(04): 221-229.
[14] 葛友涛, 蒋秋子, 卞廷松, 肖倩倩. 中药复方治疗男性迟发性性腺功能减退症的组方规律及分子机制[J/OL]. 中华老年病研究电子杂志, 2023, 10(03): 43-50.
[15] 孙攀喜, 魏丽丽, 陈勇, 樊东升. 王不留行黄酮苷对小鼠缺血性脑损伤的影响[J/OL]. 中华脑血管病杂志(电子版), 2025, 19(03): 220-227.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?